Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis.
OBJECTIVE
To determine the value of a hemodialysis graft surveillance program in reducing the incidence of graft thrombosis and prolonging graft patency by means of early detection and percutaneous transluminal angioplasty (PTA) of graft-related stenoses.


METHODS
For 4-1/2 years, routine graft examination and measurement of several dialysis parameters were used to identify 106 cases of suspected graft dysfunction in 57 patients (56 men, one woman; aged 27-76 years). Graft-related stenoses detected with angiography were treated with PTA.


RESULTS
Abnormal physical examination findings were the most common sole indication of graft dysfunction. Of the 106 cases referred for angiographic evaluation, 97 (92%) had at least one lesion. PTA was successful in 88 of 90 treated cases. The primary patency rates at 1 year were 16% for arteriovenous fistulas (AVFs) and 23% for polytetrafluoroethylene (PTFE) grafts. Early detection of stenoses by means of surveillance and repeated PTA enabled 1-year primary assisted patency rates of 67% for AVFs and 68% for PTFE grafts. The incidence of graft thrombosis fell from 48% in 1988 to 17% in 1994 (P < .001).


CONCLUSIONS
The hemodialysis graft surveillance program resulted in a statistically significant reduction in the incidence of graft thrombosis. Although primary patency rates after PTA were low, repeated PTA of detected stenoses allowed good primary assisted patency rates.
Safa
A A
AA
Department of Radiology, University of California San Diego Medical Center 92103, USA.
Valji
K
K
Roberts
A C
AC
Ziegler
T W
TW
Hye
R J
RJ
Oglevie
S B
SB
D000328:Adult; D000368:Aged; D015901:Angiography, Digital Subtraction; D015906:Angioplasty, Balloon, Coronary; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D001807:Blood Vessel Prosthesis; D005260:Female; D005542:Forearm / Q000098:blood supply; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011159:Population Surveillance; D006435:Renal Dialysis; D013927:Thrombosis / Q000453:epidemiology* / Q000517:prevention & control
D011138:Polytetrafluoroethylene